Gavi HPV Programs: Application to Implementation.
Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings.
Gavi The Vaccine Alliance Secretariat, 2 Chemin des Mines, Geneva 10 CH-1211, Switzerland. cmh558@nyu.edu.
Celina M
CM
Hanson
Department of Obstetrics and Gynecology, University of Washington, Box 359865, 325 9th Avenue, Seattle, WA 98104, USA. eckert@uw.edu.
Linda
L
Eckert
World Health Organization, Department of Immunization, Vaccines and Biologicals, 20 Avenue Appia, Geneva 27 CH-1211, Switzerland. bloemp@who.int.
Paul
P
Bloem
World Health Organization, Department of Immunization, Vaccines and Biologicals, 20 Avenue Appia, Geneva 27 CH-1211, Switzerland. cernuschit@who.int.
Tania
T
Cernuschi
HPV; cervical cancer; vaccination